Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Solid Biosciences (SLDB) Non Operating Income (2017 - 2024)

Solid Biosciences (SLDB) has disclosed Non Operating Income for 8 consecutive years, with -$7.1 million as the latest value for Q4 2024.

  • Quarterly Non Operating Income fell 195.52% to -$7.1 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$1.6 million through Dec 2024, down 113.44% year-over-year, with the annual reading at $4.9 million for FY2025, 648.62% up from the prior year.
  • Non Operating Income hit -$7.1 million in Q4 2024 for Solid Biosciences, down from $211000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $7.4 million in Q4 2023 to a low of -$7.1 million in Q4 2024.
  • Historically, Non Operating Income has averaged $543700.0 across 5 years, with a median of $46000.0 in 2021.
  • Biggest five-year swings in Non Operating Income: crashed 1500.0% in 2021 and later soared 4354.55% in 2023.
  • Year by year, Non Operating Income stood at -$131000.0 in 2020, then skyrocketed by 132.06% to $42000.0 in 2021, then crashed by 945.24% to -$355000.0 in 2022, then soared by 2187.89% to $7.4 million in 2023, then plummeted by 195.52% to -$7.1 million in 2024.
  • Business Quant data shows Non Operating Income for SLDB at -$7.1 million in Q4 2024, $211000.0 in Q3 2024, and $2.7 million in Q2 2024.